Daewoong received the clinical permission for ‘NOVOSIS’, an innovative medical device

- If successful, the first medical device used in
  bone graft treatments such as implant in Korea

- Plan to be released in the first half of next year
  after an 8 month of clinical trial

Daewoong Pharmaceutical Co., Ltd. (CEO Lee, Jong Wook) obtains an authorization for ‘NOVOSIS’, a complex between bone graft materials and BMP-2(a protein of osteoplastic promotion) as new medical device. NOVOSIS will be released in the first half next year after 8-month clinical trials. This outcome is the first time internally and second time in the world. It is the first development of a medical device combining bone graft material and BMP-2 in Korea and the second in the world.

NOVOSIS is used in various ways including treatment for bone graft like implants. Especially, for the patients, who have suffered with weak gingival, NOVOSIS helps keep gingival strong to fix implant quickly. It is expected to reduce patients’ suffering. According to the person from Daewoong, NOVOSIS is expected to shorten the period of fixing implants by half than before and help prevent initial side effect such as lack of osteointegration.

Daewoong’s Novosis is being planned to enter the global market including America and Japan. Since the global market of bone graft materials has been monopolized by one of the foreign pharmaceutical companies, patients are significantly burdened with high prices. Based on its bio-technology using genetic engineering, Novosis will be provided with excellent effects and relatively low prices.